One-year mortality (%, 95% CI) subdivided by age, gender and test result
| Untested (n=39 928) | Normal inflammatory markers (n=111 528) | Any raised inflammatory marker (n=47 797) | Raised CRP (n=29 164) | Raised ESR (n=23 138) | Raised PV (n=4568) | |
| Overall (n=199 253) | 1.62 (1.50 to 1.75) | 1.41 (1.34 to 1.48) | 6.89 (6.66 to 7.11) | 8.76 (8.43 to 9.08) | 4.99 (4.71 to 5.27) | 4.66 (4.05 to 5.27) |
| Age | ||||||
| <30 (n=21 732) | 0.09 (0.02 to 0.18) | 0.04 (0.01 to 0.08) | 0.08 (0.00 to 0.17) | 0.13 (0.00 to 0.27) | 0.00 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| 30–39 (n=22 718) | 0.04 (0.00 to 0.10) | 0.08 (0.03 to 0.13) | 0.37 (0.19 to 5.47) | 0.50 (0.23 to 0.77) | 0.28 (0.06 to 0.51) | 0.0 (0.00 to 0.00) |
| 40–49 (n=31 588) | 0.19 (0.08 to 0.30) | 0.15 (0.09 to 0.20) | 1.12 (0.86 to 1.39) | 1.54 (1.14 to 1.95) | 0.92 (0.59 to 1.25) | 0.90 (0.01 to 1.69) |
| 50–59 (n=35 044) | 0.41 (0.26 to 0.56) | 0.41 (0.32 to 0.49) | 2.37 (2.03 to 2.70) | 2.98 (2.48 to 3.47) | 1.79 (1.38 to 2.21) | 1.62 (0.75 to 2.50) |
| 60–69 (n=35 094) | 0.84 (0.62 to 1.05) | 0.91 (0.78 to 1.05) | 4.96 (4.51 to 5.40) | 6.72 (6.05 to 7.39) | 3.88 (3.33 to 4.43) | 3.27 (2.12 to 4.42) |
| 70–79 (30, 251) | 2.27 (1.90 to 2.64) | 2.51 (2.26 to 2.76) | 9.39 (8.77 to 10.0) | 11.38 (10.5 to 12.2) | 7.35 (6.54 to 8.16) | 6.32 (4.75 to 7.88) |
| >80 (22, 826) | 8.88 (8.05 to 9.70) | 8.61 (8.07 to 9.16) | 21.8 (20.9 to 22.7) | 25.9 (24.7 to 27.1) | 16.1 (14.9 to 17.3) | 15.6 (12.9 to 18.3) |
| Gender | ||||||
| Male (n=75 787) | 1.86 (1.64 to 2.07) | 1.58 (1.46 to 1.70) | 9.78 (9.33 to 10.2) | 11.48 (10.9 to 12.1) | 7.98 (7.35 to 8.61) | 6.63 (5.44 to 7.81) |
| Female (n=1 23 466) | 1.48 (1.33 to 1.63) | 1.30 (1.22 to 1.39) | 5.29 (5.04 to 5.54) | 6.99 (6.61 to 7.36) | 3.65 (3.36 to 3.94) | 3.51 (2.84 to 4.18) |
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; PV, plasma viscosity.